HEALTH

Joint Juice names CEO

BY Michael Johnsen

SAN FRANCISCO Joint Juice earlier this week named David Ritterbush the company’s new CEO. Ritterbush, who makes the transition from COO, has been with the joint health nutrition company since 2009.

"As chief operating officer, David has proven his ability as a strong and motivating leader with a clear understanding of the benefits and opportunities for Joint Juice," stated Joint Juice board member Mark Slezak. "[His] impressive industry knowledge and experience will undoubtedly position Joint Juice for further brand growth and expansion."

 

With more than 20 years of experience in the consumer packaged goods industry, Ritterbush began his career with Dreyer’s Grand Ice Cream. Over the span of his tenure with the organization, Dreyer’s grew from a $300 million company to a $2 billion company.

 

 

Most recently, Ritterbush was VP and general manager for Red Bull North America, the leading global energy drink company, where he was responsible for all distribution, marketing and sales in the western United States.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

FDA tentatively approves generic Crestor

BY Alaric DeArment

MUMBAI, India The Food and Drug Administration has given tentative approval to a generic cholesterol drug made by Sun Pharmaceutical Industries.

Sun announced Wednesday the tentative approval of rosuvastatin calcium tablets in the 5-mg, 10-mg, 20-mg and 40-mg strengths.

The drug is a generic version of AstraZeneca’s Crestor, which had annual sales of around $3.4 billion in the United States, according to Sun. Sun did not disclose when it would begin marketing its version of the drug, though Crestor will lose patent protection for use in adults in December 2021, according to FDA data.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Walgreens names SVP pharmaceutical development, market access

BY Allison Cerra

DEERFIELD, Ill. Walgreens announced Thursday that Jeffrey Berkowitz, a former SVP at drug maker Merck, has joined the company.

Berkowitz will serve as Walgreens’ SVP pharmaceutical development and market access, responsible for the overall pharmacy contracting strategy for the company, both on the pharmaceutical manufacturing side and on the retail payer side, the drug store chain said. He will report to Walgreens’ pharmacy services president Kermit Crawford.

“As we continue our efforts to transform community pharmacy, Jeff will play a vital role in working with our partners in the pharmaceutical industry, and across the entire healthcare sector, to develop strategies in collaboration with our sales and services organization that will provide better adherence and clinical outcomes for patients,” Crawford said. “In addition, Jeff’s exceptional experience, expertise and track record of growth and success in the pharmaceutical industry will be important to further enhancing our pharmacy, health-and-wellness solutions.”

Prior to joining Walgreens, Berkowitz served as SVP global market access at Merck, part of the Merck global human health leadership team, responsible for all activity related to access, pricing, payer marketing, health outcomes and health technology assessments worldwide.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?